0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

CHLORAMPHENICOL (CHLOROMYCETIN®) THERAPY IN SHIGELLA ENTERITIS

SIDNEY ROSS, M.D.; FREDERIC G. BURKE, M.D.; E. CLARENCE RICE, M.D.; JOHN A. WASHINGTON, M.D.; SARA STEVENS, B.S.
JAMA. 1950;143(17):1459-1460. doi:10.1001/jama.1950.02910520001001.
Text Size: A A A
Published online

The in vitro bacteriostatic effect of sulfonamides against organisms of the genus Shigella together with the clinical efficacy of the drug in this disease has been amply demonstrated.1 The soluble, easily absorbed sulfonamides such as sulfadiazine have been shown to be superior to the enteric preparations such as succinylsulfathiazole (sulfasuxidine®) and sulfaguanidine.1 However, the limiting factors in the routine employment of sulfadiazine in shigellosis include: (1) the not infrequent appearance of sulfonamide-resistant strains of Shigella organisms, (2) the occasional patient with a sensitivity to sulfonamide and (3) the possible hazard of administering sulfadiazine to dehydrated patients in the tropical areas where the disease has its greatest endemic concentration.

Therefore, the search continues for a drug with the activity of sulfadiazine against Shigella organisms but lacking its undesirable effects. Penicillin has been found to be of no value. We recently reported on the efficacy of oral administration of polymyxin

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();